GlassScriptPhysician profile
Eva A Edwards
NPI 1396964102
$14,023.30
in general payments reported to CMS, 2019-2025
30 companies · $1,399 in 2025
The $1,399 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,525 · 2022: $5,664 · 2023: $4,109 · 2024: $1,325 · 2025: $1,399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,984 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,750 · Travel and Lodging: $99.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,984.04 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,750.00 |
| Travel and Lodging | $99.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $8,534.61 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,489.98 | 2021-2025 | Relistor, Xifaxan, Trulance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $636.04 | 2021-2025 | Caplyta |
| Indivior INC. | $394.05 | 2022-2025 | Sublocade |
| Otsuka America Pharmaceutical, INC. | $384.02 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Braeburn INC. | $352.29 | 2023-2025 | Brixadi |
| Biodelivery Sciences International, INC. | $278.81 | 2021 | |
| Amgen INC. | $266.31 | 2021-2025 | Otezla, Repatha |
| Alkermes, INC. | $252.13 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Astrazeneca Pharmaceuticals LP | $180.69 | 2024-2025 | |
| Lilly USA, LLC | $166.29 | 2021-2025 | Mounjaro, Zepbound |
| Axsome Therapeutics, INC. | $162.58 | 2022-2025 | Auvelity |
| Ardelyx, INC. | $126.55 | 2025 | Ibsrela |
| Novo Nordisk INC | $121.07 | 2021-2025 | Wegovy |
| Vanda Pharmaceuticals INC. | $119.83 | 2025 | Fanapt, Hetlioz |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $96.83 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.14 | 2021 | |
| Pfizer INC. | $69.04 | 2024-2025 | |
| Dexcom, INC. | $56.93 | 2022-2023 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $36.24 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $32.88 | 2021 | |
| Nestle Healthcare Nutrition INC. | $30.16 | 2022-2023 | |
| Ipsen Biopharmaceuticals, INC | $27.93 | 2025 | Onivyde |
| Boston Scientific Corporation | $27.13 | 2023 | Rezum Generator |
| Gilead Sciences, INC. | $26.47 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $26.18 | 2025 | Cobenfy |
| Glaxosmithkline, LLC. | $16.90 | 2021 | |
| Smith+Nephew, INC. | $15.29 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $13.52 | 2023 | Dupixent |
| Novartis Pharmaceuticals Corporation | $11.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eva Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.